Qiagen NV (NASDAQ:QGEN)‘s stock had its “neutral” rating reiterated by equities researchers at DZ Bank AG in a research note issued to investors on Monday.

Other equities research analysts have also issued research reports about the stock. Commerzbank Ag restated a “buy” rating on shares of Qiagen NV in a research note on Wednesday, January 25th. Zacks Investment Research lowered shares of Qiagen NV from a “hold” rating to a “sell” rating in a research note on Tuesday, January 17th. Deutsche Bank AG restated a “buy” rating on shares of Qiagen NV in a research note on Tuesday, May 2nd. Jefferies Group LLC restated a “hold” rating on shares of Qiagen NV in a research note on Friday, February 3rd. Finally, Barclays PLC restated a “buy” rating and set a $33.00 price target on shares of Qiagen NV in a research note on Friday, May 5th. Seven analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Qiagen NV presently has an average rating of “Hold” and a consensus target price of $28.36.

Analyst Recommendations for Qiagen NV (NASDAQ:QGEN)

Qiagen NV (NASDAQ:QGEN) traded up 0.81% during mid-day trading on Monday, hitting $32.48. The company had a trading volume of 354,421 shares. Qiagen NV has a 12-month low of $20.71 and a 12-month high of $32.52. The company’s 50 day moving average price is $29.53 and its 200-day moving average price is $28.93. The firm has a market capitalization of $7.39 billion, a PE ratio of 90.22 and a beta of 1.05.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/05/15/dz-bank-ag-reaffirms-neutral-rating-for-qiagen-nv-qgen.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Oppenheimer Asset Management Inc. acquired a new position in Qiagen NV during the first quarter worth $114,000. Fuller & Thaler Asset Management Inc. acquired a new position in Qiagen NV during the second quarter worth $116,000. First Mercantile Trust Co. acquired a new position in Qiagen NV during the second quarter worth $126,000. Societe Generale acquired a new position in Qiagen NV during the second quarter worth $152,000. Finally, SG Americas Securities LLC raised its position in Qiagen NV by 9.9% in the second quarter. SG Americas Securities LLC now owns 6,977 shares of the company’s stock worth $152,000 after buying an additional 629 shares in the last quarter. Institutional investors and hedge funds own 60.68% of the company’s stock.

Qiagen NV Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

5 Day Chart for NASDAQ:QGEN

Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with MarketBeat.com's FREE daily email newsletter.